Scholarlink

Purpose of Review <p>To inform readers about advances in cancer immunotherapy regulators of immune checkpoints and effects on the heart.</p> Recent Findings <p>In the last 3 years, five new immune checkpoint inhibitors have been approved for clinical use. Based on clinical trial results, these agents overall improve efficacy and expand cancer treatment to more patients with comparable rates of adverse cardiac events including myocarditis. Ongoing clinical trials are also evaluating other regulators of immune checkpoints, including bispecific antibodies, agonistic antibodies that activate antigen presenting cells, and activation of natural killer cells.</p> Summary <p>Immunotherapies targeting regulators of immune checkpoints continue to be at the forefront of cancer treatment. New antagonistic antibodies for PD-1 (retifanlimab, toripalimab), PDL-1 (cosibelimab), and CTLA-4 (tremelimumab), and LAG-3 (relatlimab) target immune checkpoints to enact stronger, more effective, and potentially safer treatment options, highlighting promising research advances in this field.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advances in Cancer Immunotherapy Regulators of Immune Checkpoints and Effects on the Heart

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月6日

查看全文
  • Manaal Iqbal,
  • Jesus Jimenez

摘要

Purpose of Review

To inform readers about advances in cancer immunotherapy regulators of immune checkpoints and effects on the heart.

Recent Findings

In the last 3 years, five new immune checkpoint inhibitors have been approved for clinical use. Based on clinical trial results, these agents overall improve efficacy and expand cancer treatment to more patients with comparable rates of adverse cardiac events including myocarditis. Ongoing clinical trials are also evaluating other regulators of immune checkpoints, including bispecific antibodies, agonistic antibodies that activate antigen presenting cells, and activation of natural killer cells.

Summary

Immunotherapies targeting regulators of immune checkpoints continue to be at the forefront of cancer treatment. New antagonistic antibodies for PD-1 (retifanlimab, toripalimab), PDL-1 (cosibelimab), and CTLA-4 (tremelimumab), and LAG-3 (relatlimab) target immune checkpoints to enact stronger, more effective, and potentially safer treatment options, highlighting promising research advances in this field.